Annual Report — Form 10-K — Sect. 13 / 15(d) – SEA’34 Filing Table of Contents
Document/ExhibitDescriptionPagesSize
1: 10-K Annual Report HTML 596K
3: EX-1.3 Consulting Agreement Dated September 1, 2014 Among HTML 50K
Cell Medx Corp.Sports Asylum, Inc. and Brad
Hargreaves.
4: EX-10.15 Loan Agreement and Note Payable Dated April 20, HTML 28K 2015 Among Cell Medx Corp., and City Group LLC.
5: EX-10.16 Loan Agreement and Note Payable Dated June 17, HTML 28K
2015 Among Cell Medx Corp., and City Group LLC.
6: EX-10.17 Loan Agreement and Note Payable Dated June 29, HTML 28K
2015 Among Cell Medx Corp., and Richard Normann.
Jeffs.
7: EX-10.18 Loan Agreement and Note Payable Dated July 7, 2015 HTML 28K
Among Cell Medx Corp., and City Group LLC.
8: EX-10.19 Loan Agreement and Note Payable Dated July 9, 2015 HTML 28K
Among Cell Medx Corp., and Richard N. Jeffs.
2: EX-10.2 Consulting Agreement Dated September 1, 2014 Among HTML 50K
Cell Medx Corp.Sports Asylum, Inc. and Jean
Arnett.
9: EX-10.20 Loan Agreement and Note Payable Dated July 15, HTML 27K
2015 Among Cell Medx Corp., and Richard N. Jeffs.
10: EX-10.22 Loan Agreement and Note Payable Dated August 12, HTML 28K
2015 Among Cell Medx Corp., and Richard N. Jeffs.
11: EX-21.1 List of Subsidiaries HTML 22K
12: EX-31.1 Certification of Principal Executive Officer HTML 28K
Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002.
13: EX-31.2 Certification of Principal Financial Officer HTML 28K
Pursuant to Section 302 of the Sarbanes-Oxley Act
of 2002.
14: EX-32.1 Certification of Principal Financial Officer HTML 24K
Pursuant to 18 U.S.C. 1350 as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
15: EX-32.2 Certification of Principal Financial Officer HTML 24K
Pursuant to 18 U.S.C. 1350 as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
48: R1 Document and Entity Information HTML 50K
39: R2 Consolidated Balance Sheets (Audited) HTML 76K
46: R3 Balance Sheets (Parenthetical) HTML 29K
50: R4 Consolidated Statements of Operations (Audited) HTML 61K
63: R5 Consolidated Statement of Shareholders Deficit HTML 50K
40: R6 Consolidated Statements of Cash Flows (Audited) HTML 89K
45: R7 Note 1- Organization and Nature of Operations HTML 30K
36: R8 Note 2 - Summary of Significant Accounting HTML 40K
Policies
29: R9 Note 3 - Technology HTML 29K
64: R10 Note 4 - Related Party Transactions HTML 44K
52: R11 Note 5 - Management Consulting Agreement HTML 28K
51: R12 Note 6 - Equipment HTML 30K
56: R13 Note 7 - Inventory HTML 25K
57: R14 Note 8 - Notes and Advances Payable HTML 35K
55: R15 Note 9 - Share Capital HTML 49K
58: R16 Note 10 - Income Taxes HTML 40K
47: R17 Note 11 - Subsequent Events HTML 29K
49: R18 Note 2 - Summary of Significant Accounting HTML 79K
Policies (Policies)
54: R19 Note 3 - Technology (Tables) HTML 28K
68: R20 Note 4 - Related Party Transactions (Tables) HTML 41K
60: R21 Note 6 - Equipment (Tables) HTML 27K
42: R22 Note 8 - Notes and Advances Payable (Tables) HTML 29K
53: R23 Note 9 - Share Capital (Tables) HTML 45K
44: R24 Note 10 - Income Taxes (Tables) HTML 38K
25: R25 Note 11 - Subsequent Events (Tables) HTML 28K
61: R26 Note 2 - Summary of Significant Accounting HTML 23K
Policies (Details Narrative)
65: R27 Note 3 - Technology - Schedule of Vesting HTML 34K
Conditions, Options issued as acquision costs
(Details)
32: R28 Note 3 - Technology (Details Narrative) HTML 29K
31: R29 Note 4 - Related Party Transactions - Schedule, HTML 36K
Amounts Due to Related Parties (Details)
34: R30 Note 4 - Related Party Transactions - Schedule of HTML 39K
Transactions with Related Parties (Details)
35: R31 Note 4 - Related Party Transactions (Details HTML 23K
Narrative)
37: R32 Note 5 - Management Consulting Agreement (Details HTML 41K
Narrative)
24: R33 Note 6 - Equipment - Amortization schedule, HTML 30K
equipment (Details)
59: R34 Note 8 - Notes and Advances Payable - Schedule of HTML 40K
Short Term Loans and Advances (Details)
41: R35 Note 8 - Notes and Advances Payable (Details HTML 41K
Narrative)
43: R36 Note 9 - Share Capital - Schedule of Assumptions HTML 32K
(Details)
27: R37 Note 9 - Share Capital - Schedule of Changes in HTML 45K
Stock Options (Details)
67: R38 Note 9 - Share Capital - Schedule of outstanding HTML 33K
options (Details)
22: R39 Note 9 - Share Capital (Details Narrative) HTML 53K
38: R40 Note 10 - Income Taxes - Schedule of components of HTML 48K
income tax expense/benefit (Details)
62: R41 Note 10 - Income Taxes - Deferred income tax HTML 32K
assets (Liabilities) (Details)
26: R42 Note 10 - Income Taxes (Details Narrative) HTML 28K
30: R43 Note 11 - Subsequent Events - Stock Option Vesting HTML 27K
Schedule, CEO Options (Details)
33: R44 Note 11 - Subsequent Events (Details Narrative) HTML 34K
66: XML IDEA XML File -- Filing Summary XML 100K
23: EXCEL IDEA Workbook of Financial Reports XLSX 44K
18: EX-101.INS XBRL Instance -- cmxc-20150531 XML 438K
16: EX-101.CAL XBRL Calculations -- cmxc-20150531_cal XML 129K
17: EX-101.DEF XBRL Definitions -- cmxc-20150531_def XML 92K
19: EX-101.LAB XBRL Labels -- cmxc-20150531_lab XML 559K
20: EX-101.PRE XBRL Presentations -- cmxc-20150531_pre XML 368K
21: EX-101.SCH XBRL Schema -- cmxc-20150531 XSD 116K
28: ZIP XBRL Zipped Folder -- 0001594062-15-000262-xbrl Zip 57K
‘EX-10.15’ — Loan Agreement and Note Payable Dated April 20, 2015 Among Cell Medx Corp., and City Group LLC.
City Group LLC (the “Lender”) of 1201 Orange Street, Suite 600, Wilmington, DE19801, advanced total of USD$10,000 (the “Principal Sum”) to Cell MedX Corp. (the “Borrower”) of 4575 Dean Martin Drive, STE 2206, Las Vegas, NV89103. The Lender advanced the funds on April 20, 2015
via payment made directly to Emerging Growth, LLC (dba TDM Financial) on account of the Borrower as a payment for the Shareholder Development Program dated April 13, 2015.
The Borrower agrees to repay the Principal Sum on demand, together with interest calculated and compounded monthly at the rate of six (6) per cent per year (the “Interest”) from April 20, 2015. The Borrower is liable for repayment for the Principal Sum and accrued Interest and any costs that the Lender incurs in trying to collect the Principal Sum and the Interest.
The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form.
For value received Cell MedX Corp., (the “Borrower”) promises to pay on demand to the order of City Group LLC (the “Lender”) the sum of $10,000 lawful money of United States of America (the “Principal Sum”) together with interest on the Principal Sum from April 20, 2015 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.
For the purpose of this promissory note, Interest Rate means six (6) per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.17% per annum calculated monthly), and is payable together with the Principal Sum when the Principal Sum is repaid.
The Borrower may repay the Principal Sum and the Interest in whole or in part at any time.
The Borrower waives presentment, protest, notice of protest and notice of dishonour of this promissory note.
